NCT05285033View on ClinicalTrials.gov

RW Effectiveness of Lurbinectedin in Extensive Stage SCLC

CompletedOBSERVATIONAL
Enrollment

312

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Lurbinectedin

Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program).

Trial Locations (2)

Unknown

Institut Curie, Paris

Villefranche-Sur-Saône - CH, Villefranche-sur-Saône

Sponsors

Collaborators (1)

PharmaMar
All Listed Sponsors
collaborator

Groupe Francais De Pneumo-Cancerologie

OTHER

collaborator

PharmaMar

INDUSTRY

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT05285033 - RW Effectiveness of Lurbinectedin in Extensive Stage SCLC | Biotech Hunter | Biotech Hunter